Fibrinogen and coronary risk

被引:23
作者
Koenig W. [1 ]
机构
[1] Department of Internal Medicine II, Cardiology, University of Ulm Medical Center, D-89081, Ulm
关键词
Fibrinogen; Fibrinogen Level; Coronary Risk; Arterioscler Thromb Vasc Biol; Plasma Fibrinogen;
D O I
10.1007/s11886-999-0068-y
中图分类号
学科分类号
摘要
The notion that fibrinogen is strongly, consistently, and independently related to coronary risk has been widely accepted. The evidence is based on numerous prospective epidemiological studies and clinical observations. However, the reasons why fibrinogen is elevated in coronary disease and in atherosclerosis are only incompletely understood. All cells involved in the atherogenetic process are able to produce cytokines which induce an acute phase reaction. The potential pathophysiologic mechanisms by which elevated fibrinogen levels mediate coronary risk are manifold: It forms the substrate for thrombin and represents the final step in the coagulation cascade; it is essential for platelet aggregation; it modulates endothelial function; it promotes smooth muscle cell proliferation and migration; it interacts with the binding of plasminogen with its receptor; and finally it represents a major acute phase protein. Whether or not fibrinogen is causally involved in atherothrombogenesis still remains to be determined, and even though other unsolved issues await conclusive answers, fibrinogen has emerged as an important additional marker of coronary risk. Copyright © 1999 by Current Science Inc.
引用
收藏
页码:112 / 118
页数:6
相关论文
共 69 条
[61]  
Prisco D., Paniccia R., Bandinelli B., Et al., Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease, Int J Clin Lab Res, 28, pp. 170-173, (1998)
[62]  
Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study, Thromb Haemost, 75, pp. 476-480, (1996)
[63]  
Frohlich M., Schunkert H., Hense H.W., Et al., Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women, Br J Haematol, 100, pp. 577-581, (1998)
[64]  
Lip G.Y.H., Blann A.D., Jones A.F., Et al., Effects of hormonereplacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis, Am Heart J, 134, pp. 764-771, (1997)
[65]  
Walsh B.W., Kuller L.H., Wild R.A., Et al., Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women, J Am Med Assoc, 279, pp. 1445-1451, (1998)
[66]  
Giri S., Thompson P.D., Taxel P., Et al., Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men, Atherosclerosis, 137, pp. 359-366, (1998)
[67]  
O'Keefe J.H., Kim S.C., Hall R.R., Et al., Estrogen replacement therapy after coronary angioplasty in women, J Am Coll Cardiol, 29, pp. 1-5, (1997)
[68]  
Hulley S., Grady D., Bush T., Et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, J Am Med Assoc, 280, pp. 605-613, (1998)
[69]  
Rosenson R.S., Tangney C.C., Hafner J.M., Intra-individual variability of fibrinogen levels and cardiovascular profile, Arterioscler Thromb, 14, pp. 1928-1932, (1994)